
Daniel Dauch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9604425/publications.pdf Version: 2024-02-01



DANIEL DALICH

#	Article	IF	CITATIONS
1	LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer, 2021, 2, 201-217.	13.2	27
2	Exploiting lipotoxicity for the treatment of liver cancer. British Journal of Cancer, 2021, 125, 1459-1461.	6.4	2
3	Selective targeting of the αC and DFG-out pocket in p38 MAPK. European Journal of Medicinal Chemistry, 2020, 208, 112721.	5.5	12
4	Platelet GPlbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine, 2019, 25, 641-655.	30.7	259
5	Cardiac glycosides are broad-spectrum senolytics. Nature Metabolism, 2019, 1, 1074-1088.	11.9	207
6	Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma (HCC). Molecular and Cellular Proteomics, 2018, 17, 810-825.	3.8	65
7	Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling. PLoS Computational Biology, 2018, 14, e1006458.	3.2	59
8	Optimized Target Residence Time: Typeâ€I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R‧pine. Angewandte Chemie - International Edition, 2017, 56, 5363-5367.	13.8	20
9	Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal of Pathology, 2017, 187, 228-235.	3.8	26
10	A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nature Medicine, 2016, 22, 744-753.	30.7	207
11	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	1.3	103
12	Prosurvival function of the cellular apoptosis susceptibility/importin-α1 transport cycle is repressed by p53 in liver cancer. Hepatology, 2014, 60, 884-895.	7.3	29
13	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
14	A Direct InÂVivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration. Cell, 2013, 153, 389-401.	28.9	127
15	A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas. Cancer Cell, 2013, 23, 784-795.	16.8	169
16	A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage. Cell, 2012, 148, 1001-1014.	28.9	296
17	Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 2011, 479, 547-551.	27.8	1,208